Drug intelligence / Profile preview

MU001

Development stage: Phase 2
Lead developer: Universidad de Chile
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Topical

Overview

**MU001** is an investigational topical wound-healing formulation delivered in a patch for diabetic foot ulcers. The formulation contains slime or mucus from *Helix aspersa* Müller, also referred to as *Cryptophalus aspersus*, together with calendula extract, propolis, and excipients. It was evaluated as an adjunct to standard care in a randomized Phase I/II clinical study sponsored by Universidad de Chile, with treatment planned for up to 60 days.

Beyond the preview

Go deeper on MU001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MU001.

Explore the full profile